Compare KELYB & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | VSTM |
|---|---|---|
| Founded | 1946 | 2010 |
| Country | United States | United States |
| Employees | 4900 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.2M | 470.7M |
| IPO Year | N/A | 2011 |
| Metric | KELYB | VSTM |
|---|---|---|
| Price | $17.96 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 2.5K | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $0.72 | $282.64 |
| Revenue Next Year | N/A | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $8.38 | $3.55 |
| 52 Week High | $125.00 | $11.25 |
| Indicator | KELYB | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 40.35 |
| Support Level | $11.84 | N/A |
| Resistance Level | $18.11 | $4.53 |
| Average True Range (ATR) | 0.98 | 0.27 |
| MACD | -0.19 | 0.03 |
| Stochastic Oscillator | 27.77 | 40.82 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.